



Figure 1




SW2 cells in medium with 100 µg/ml HE2, hour 0




SW2 cells in medium with 100 µg/ml, hour 4

09889300 091301

Figure 2



SW2 cells in medium, hour 0



SW2 cells in medium, hour 4

09889300-091301

Figure 3

**Vaccination of goats with HE2-F(ab)'2:
Serum Ig with specificity for HE2**





Figure 4

Vaccination of goats with HE2-F(ab)'2:
Binding of serum Ig to Ep-CAM positive
human stomach cancer cells (KATO III)



09889300-091301

Figure 5

Vaccination of goats with HE2-F(ab)'2:
Binding of serum Ig to Ep-CAM negative
human melanoma cells (WM9)





Figure 6

Vaccination of goats with HE2-F(ab)'₂:
Binding of affinity-purified serum Ig to Ep-CAM positive
human stomach cancer cells (KATO III)



09889300-091301

Figure 7

Vaccination of goats with HE2-F(ab)'₂:
Binding of affinity-purified serum Ig to Ep-CAM negative
human melanoma cells




Figure 8

Vaccination of rhesus monkeys with HE2
Binding of serum Ig to HE2





Figure 9

Vaccination of rhesus monkeys with HE
Binding of serum Ig to Kato III tumor cells



10/13

Figure 10

Study of rhesus monkeys
Titer of antibodies against HE2




Figure 11

Study with rhesus monkeys:
Serum Ig against Kato III tumor cells




Figure 12

**Vaccination of a patient with intestinal cancer with HE2:
Induction of antibodies against human
stomach cancer cells (KATO III)**





Figure 13

**Vaccination of a patient with intestinal cancer with HE2:
Induction of serum cytotoxicity against human
stomach cancer cells (KATO III)**



09/889300-091301